Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Araxes Pharma LLC is currently managing 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 2 actions are located in 2 distinct art units, indicating that each filing falls into a different technical classification. Each action is being reviewed by a different person, as there are 2 distinct examiners involved in the prosecution. This distribution across 2 examiners for 2 actions means that every pending matter has a unique point of contact at the patent office.
DIAMOND, ALAN D is the busiest examiner, with 1 pending office action assigned. With 2 distinct examiners for 2 actions, the workload is evenly split between the assigned individuals. The use of 2 distinct art units for only 2 actions shows that the company's current pharmaceutical filings are technically diverse despite the small number of pending matters. For the practitioner, this requires managing two separate examiner relationships and two different art unit standards simultaneously to advance the 2 pending office actions. The lack of examiner or art unit overlap means each filing must be handled as an independent matter.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| No statute on record | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DIAMOND, ALAN D | 1 | 71.5% | +8.5% |
| WILLIS, DOUGLAS M | 1 | 82.4% | +19.7% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18416739 | SUBSTITUTED PIPERAZINES AS INHIBITORS OF KRAS G12C | WILLIS, DOUGLAS M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18416739 | SUBSTITUTED PIPERAZINES AS INHIBITORS OF KRAS G12C | WILLIS, DOUGLAS M | — |
| Art Unit | Apps |
|---|---|
| 3991 | 1 |
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19237891 | COVALENT INHIBITORS OF KRAS G12C | DIAMOND, ALAN D | 3991 | Other | Final Rejection | — | Pending | Jun 13, 2025 |
| 18416739 | SUBSTITUTED PIPERAZINES AS INHIBITORS OF KRAS G12C | WILLIS, DOUGLAS M | 1624 | §112 | Non-Final OA | — | Pending | Jan 18, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAraxes Pharma LLC has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Alan D Diamond has the most, with 1 of Araxes Pharma LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
